Overview
Mentions in press and media 10
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 14, 2024 | Salipro Biotech Obtains Grant for Key Patent from the European Patent Office | Salipro Biotech Obtains Grant for Key Patent from the European Patent Office Thu, Mar 14, 2024 10:00 CET Report this content This additional European patent will further strengthen Salipro Biotech’s integrated IP portfolio protecting its pr... |
| Oct 10, 2023 | Salipro Biotech and Icosagen Launch Antibody Discovery Collaboration | Salipro Biotech and Icosagen Launch Antibody Discovery Collaboration Tue, Oct 10, 2023 09:00 CET Report this content Salipro Biotech and Icosagen announce the initiation of a multi-target collaboration for the discovery and characterization... |
| Sep 12, 2023 | Salipro Biotech enters into research collaboration with Sumitomo Pharma to advance a drug discovery program | Salipro Biotech enters into research collaboration with Sumitomo Pharma to advance a drug discovery program Tue, Sep 12, 2023 09:00 CET Report this content The collaboration leverages Salipro Biotech’s unique expertise and its Salipro® plat... |
| Jun 13, 2023 | Salipro Biotech Expands Global Intellectual Property Portfolio with Granted Patent in Japan | Salipro Biotech Expands Global Intellectual Property Portfolio with Granted Patent in Japan Tue, Jun 13, 2023 09:00 CET Report this content Salipro Biotech obtains granted patent in Japan, protecting its proprietary Salipro® platform techno... |
| May 9, 2023 | Salipro Biotech and DyNAbind Announce Milestone Achievement in Collaboration to Enable DEL for Membrane Proteins | Salipro Biotech and DyNAbind Announce Milestone Achievement in Collaboration to Enable DEL for Membrane Proteins Tue, May 09, 2023 09:00 CET Report this content The two biotech companies report that they have successfully screened and ident... |
| Mar 28, 2023 | Salipro Biotech publishes research in Scientific Reports on structure-function studies for membrane proteins in collaboration with AstraZeneca | Salipro Biotech publishes research in Scientific Reports on structure-function studies for membrane proteins in collaboration with AstraZeneca Tue, Mar 28, 2023 12:00 CET Report this content Stockholm, March 28, 2023 – Salipro Biotech today... |
| Nov 8, 2022 | Salipro Biotech enters into collaboration and license agreement with Sanofi to advance discovery programs | Salipro Biotech enters into collaboration and license agreement with Sanofi to advance discovery programs Tue, Nov 08, 2022 12:00 CET Report this content The collaboration combines Salipro Biotech’s unique expertise and its Salipro® platfor... |
| Sep 7, 2022 | Salipro Biotech Obtains Granted Patents in the United States and China for Direct Extraction of Membrane Proteins and Library Generation | Salipro Biotech Obtains Granted Patents in the United States and China for Direct Extraction of Membrane Proteins and Library Generation Wed, Sep 07, 2022 09:00 CET Report this content Salipro Biotech strengthens its IP portfolio protecting... |
| Oct 12, 2021 | Salipro Biotech enters into a collaboration and license agreement with AbCellera for access to the Salipro® Platform for antibody discovery against GPCRs, ion channels, and transporters | Salipro Biotech enters into a collaboration and license agreement with AbCellera for access to the Salipro® Platform for antibody discovery against GPCRs, ion channels, and transporters Tue, Oct 12, 2021 09:03 CET The collaboration enables ... |
Reviews 0
FAQ about Salipro Biotech AB
When was Salipro Biotech AB founded?
Salipro Biotech AB was founded in 2016.
What has the press written about Salipro Biotech AB?
Parsers VC has collected 10 articles mentioning Salipro Biotech AB, among them “Salipro Biotech Obtains Grant for Key Patent from the European Patent Office” (Mar 14, 2024) and “Salipro Biotech and Icosagen Launch Antibody Discovery Collaboration” (Oct 10, 2023).
Is Salipro Biotech AB still active?
Yes, Salipro Biotech AB is active; its latest activity on Parsers VC dates from Dec 5, 2024.